Based on 1 analyst offering 12 month price targets for Phio Pharmaceuticals Corp
Min Forecast
$4.00+41.34%
Avg Forecast
$4.00+41.34%
Max Forecast
$4.00+41.34%
Should I buy or sell PHIO stock?
Based on 1 analyst offering ratings for Phio Pharmaceuticals Corp.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PHIO's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PHIO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More
Be the first to know when Wall Street analysts revise their PHIO stock forecasts and price targets.
PHIO stock forecasts by analyst
Analyst / Firm
Rating
Action
Price Target
Upside/Downside
Date
Analyst Color
locked
locked
$00.00
+00.00%
2025-04-08
1 of 1
Forecast return on equity
Is PHIO forecast to generate an efficient return?
Company
N/A
Industry
1,575.97%
Market
76.96%
Forecast return on assets
Is PHIO forecast to generate an efficient return on assets?
Company
N/A
Industry
1,136.33%
PHIO earnings per share forecast
What is PHIO's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$4.30
PHIO revenue forecast
What is PHIO's revenue in the next 1 years based on estimates from 1 analyst?
Is Phio Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: PHIO) stock is to Buy PHIO stock.
Out of 1 analyst, 0 (0%) are recommending PHIO as a Strong Buy, 1 (100%) are recommending PHIO as a Buy, 0 (0%) are recommending PHIO as a Hold, 0 (0%) are recommending PHIO as a Sell, and 0 (0%) are recommending PHIO as a Strong Sell.
What is PHIO's earnings growth forecast for 2025-2025?
(NASDAQ: PHIO) Phio Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 46.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 71.14%.
Phio Pharmaceuticals's earnings in 2025 is -$7,150,000.
In 2025, PHIO is forecast to generate $20,546,062 in earnings, with the lowest earnings forecast at $20,546,062 and the highest earnings forecast at $20,546,062.
What is PHIO's revenue growth forecast for 2025-2025?
(NASDAQ: PHIO) Phio Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 3,251.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.56%.
Phio Pharmaceuticals's revenue in 2025 is $0.
In 2025, PHIO is forecast to generate $358,361,550 in revenue, with the lowest revenue forecast at $358,361,550 and the highest revenue forecast at $358,361,550.
What is PHIO's forecast return on assets (ROA) for 2025-2026?
(NASDAQ: PHIO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 1,136.33%.
What is PHIO's Price Target?
According to 1 Wall Street analyst that have issued a 1 year PHIO price target, the average PHIO price target is $4.00, with the highest PHIO stock price forecast at $4.00 and the lowest PHIO stock price forecast at $4.00.
The Wall Street analyst predicted that Phio Pharmaceuticals's share price could reach $4.00 by Apr 8, 2026. The average Phio Pharmaceuticals stock price prediction forecasts a potential upside of 41.34% from the current PHIO share price of $2.83.
What is PHIO's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: PHIO) Phio Pharmaceuticals's current Earnings Per Share (EPS) is -$9.08. In 2025, PHIO's EPS is forecast to hit $4.30 (min: $4.30, max: $4.30).
What is PHIO's forecast return on equity (ROE) for 2025-2026?
(NASDAQ: PHIO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.